Sheng Yin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/595471/publications.pdf

Version: 2024-02-01

933447 794594 21 401 10 19 h-index citations g-index papers 22 22 22 657 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 439-449.	10.7	115
2	Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget, 2015, 6, 6670-6683.	1.8	54
3	<i>BRCA1</i> and <i>BRCA2</i> mutations in ovarian cancer patients from China: ethnicâ€related mutations in <i>BRCA1</i> associated with an increased risk of ovarian cancer. International Journal of Cancer, 2017, 140, 2051-2059.	5.1	45
4	Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study. BMC Cancer, 2015, 15, 583.	2.6	35
5	A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2 Journal of Clinical Oncology, 2020, 38, 6001-6001.	1.6	30
6	Wip1 suppresses ovarian cancer metastasis through the ATM/AKT/Snail mediated signaling. Oncotarget, 2016, 7, 29359-29370.	1.8	24
7	Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology, 2020, 31, e86.	2.2	22
8	<p>Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 2789-2798.	2.0	13
9	Significant association of the EXO1 rs851797 polymorphism with clinical outcome of ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 4841-4851.	2.0	12
10	Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. Cellular Physiology and Biochemistry, 2018, 47, 2088-2096.	1.6	11
11	<i>CREBBP</i> knockdown suppressed proliferation and promoted chemo-sensitivity via PERK-mediated unfolded protein response in ovarian cancer. Journal of Cancer, 2021, 12, 4595-4603.	2.5	7
12	A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2020, 31, e61.	2.2	6
13	Polymorphisms in the kinesin-like factor 1 B gene and risk of epithelial ovarian cancer in Eastern Chinese women. Tumor Biology, 2015, 36, 6919-6927.	1.8	5
14	Surgical and oncological outcomes of an improved nerve-sparing radical hysterectomy technique: 6 years of experience at two centres. Surgical Oncology, 2018, 27, 380-386.	1.6	5
15	An improved nerve-sparing radical hysterectomy technique for cervical cancer using the paravesico-vaginal space as a new surgical landmark. Oncotarget, 2017, 8, 90413-90420.	1.8	5
16	Role of Transdiaphragmatic Thoracic Exploration in Bulky Stage IIIC Ovarian Cancer Patients Who Underwent Diaphragmatic Surgery. International Journal of Gynecological Cancer, 2015, 25, 1392-1397.	2.5	4
17	Primary Laparoscopic Surgery Does Not Affect the Prognosis of Early-Stage Ovarian Clear Cell Cancer. Cancer Management and Research, 2021, Volume 13, 6403-6409.	1.9	4
18	Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer. Journal of Ovarian Research, 2022, 15, 56.	3.0	2

SHENG YIN

#	Article	IF	CITATIONS
19	BRCA1 and BRCA2 mutations in ovarian cancer patients from China: Association of ethnic-specific mutations in BRCA1 with an increased risk of ovarian cancer Journal of Clinical Oncology, 2017, 35, 1583-1583.	1.6	1
20	Therapeutic Role of Retroperitoneal Lymphadenectomy in 170 Patients With Ovarian Clear Cell Cancer. Frontiers in Oncology, 2021, 11, 754149.	2.8	1
21	The anatomical structure of the paravesico-vaginal space, a novel landmark for nerve-sparing radical hysterectomy. International Journal of Gynecological Cancer, 2019, 29, 441-442.	2.5	0